Chief Executive Officer
Microbiology
ViraTherapeutics
Austria
Dr. Schwer is the Chief Executive Officer of ViraTherapeutics. He served three years as CEO of Lanthio Pharma B.V., a Dutch drug development company that was acquired by MorphoSys AG. He led the company’s effort in advancing its therapeutic program from pre-clinical into clinical stage. He was co-founder and CEO of Sloning Biotechnology, a biotech company that became market leader in generating recombinant gene libraries for pharma and industrial biotech. Dr. Schwer received his PhD in clinical chemistry from University of Regensburg, was a postdoctoral fellow at Harvard Medical School at the Beth Israel Hospital and Dana-Faber Cancer Institute and holds an MBA from Henley Management College, UK.
virus-based therapeutics ,anti-cancer therapeutics